January 9, 2023 02:24 PM EST

FDA accepts one, delays another; Data, deals and dollars for slate of biotechs

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

The schizophrenia and major depressive disorder drug out of Otsuka Pharmaceutical and Lundbeck is now under priority review at the FDA for another indication. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA accepts one, delays another; Data, deals and dollars for slate of biotechs

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

FDA ac­cepts one, de­lays an­oth­er; Da­ta, deals and dol­lars for slate of biotechs

Senior Reporter

Associate Editor

Sign up to read this article for free.

FDA accepts one, delays another; Data, deals and dollars for slate of biotechs